Ono, Fate in off-the-shelf CAR T deal

Fate Therapeutics Inc. (NASDAQ:FATE) added $1.13 (10%) to $12.20 on Sept. 18 after partnering with Ono Pharmaceutical Co. Ltd. (Tokyo:4528) to develop and commercialize two off-the-shelf CAR T cell programs for cancer.

The partners said each product will incorporate Fate's induced pluripotent stem cell (iPS cell) technology and is derived from a clonal master iPS cell line engineered to eliminate endogenous TCR expression, insert a CAR into the TCR α constant (TRAC) locus and incorporate other antitumor properties. The first product targets an undisclosed antigen on lymphoblastic leukemias, and the second targets an undisclosed antigen on solid tumors...